Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Apr 9, 2010

Premium

Pietro Scalfaro has joined the board of diagnostics technology development firm Biocartis, the company said this week.

Scalfaro is chief project officer at the Debiopharm Group, which develops biologics and small-molecule drugs.

Debiopharm was one of two new investors in Biocartis in a Series B financing round announced this week that raised €30 million ($40 million). Johnson & Johnson Development was the other new investor. The firm will use the proceeds to further build out the first version of its proprietary platform, the company said in a statement.

Biocartis, founded in 2007 and based in Lausanne, Switzerland, has licensed and developed new technologies to build a "broadly applicable new diagnostics platform for low to highly multiplexed detection, quantification, and amplification of molecular-based biomarkers, including nucleic acids, proteins, and small molecules," the company said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.